Cargando…

Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial

Objectives: To identify the lowest dose of Depo-Provera that, when administered off-label subcutaneously, suppressed ovulation and had a pharmacokinetic profile consistent with a 4-month contraceptive effect. Study Design: We conducted a randomized, multicenter, parallel-group study to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpern, Vera, Fuchs, Rachael, Brache, Vivian, Bahamondes, Luis, Miranda, Maria Jose, Lendvay, Anja, Cochón, Leila, Taylor, Douglas, Dorflinger, Laneta J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551587/ https://www.ncbi.nlm.nih.gov/pubmed/34746745 http://dx.doi.org/10.1016/j.conx.2021.100070

Ejemplares similares

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results()
por: Taylor, Douglas J., et al.
Publicado: (2022)

Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial
por: Deese, Jennifer, et al.
Publicado: (2022)

Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016)

Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Precipitous Delivery Masquerading as Biliary Colic in the Setting of Depo-Provera® Failure
por: Chang, Allen D, et al.
Publicado: (2020)

Changes in body weight and blood pressure among women using Depo-Provera injection in Northwest Ethiopia
por: Zerihun, Muluken Fekadie, et al.
Publicado: (2019)

Depo-Provera® Treatment Does Not Abrogate Protection from Intravenous SIV Challenge in Female Macaques Immunized with an Attenuated AIDS Virus
por: Genescà, Meritxell, et al.
Publicado: (2010)

Levonorgestrel release rates measured through analysis of two-rod contraceptive explants
por: Fuchs, Rachael, et al.
Publicado: (2020)

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971)

ALICE proverà a fare un Big Ban in miniatura
por: Prestinenza, Luigi
Publicado: (2005)

Safety Evaluation of EXPAREL (DepoFoam Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison
por: Richard, Brigitte M., et al.
Publicado: (2011)

IUD self-removal as self-care: Research is needed in low and middle-income countries
por: Cartwright, Alice F., et al.
Publicado: (2022)

OR33-5 Low Systemic Levels of Segesterone Acetate are Required to Inhibit Ovulation in Women
por: Archer, David, et al.
Publicado: (2019)

Enhancing the Enhanced Recovery Program in Colorectal Surgery - Use of Extended-Release Epidural Morphine (DepoDur®)
por: Peravali, Rajeev, et al.
Publicado: (2014)

Conjunctival Necrosis due to Subconjunctival Methylprednisolone (Depo-Medrol™) Acetate Injection
por: van Zyl, L. M., et al.
Publicado: (2010)

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
por: Thurman, Andrea R., et al.
Publicado: (2021)

Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women()()
por: Heffron, Renee, et al.
Publicado: (2019)

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)

Effects of Long-term Use of Depo-medroxyprogesterone Acetate on Lipid Metabolism in Nepalese Women
por: Yadav, Binod Kumar, et al.
Publicado: (2011)

WHO Tiered-Effectiveness Counseling Is Rights-Based Family Planning
por: Stanback, John, et al.
Publicado: (2015)

Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant
por: Ali, Moazzam, et al.
Publicado: (2016)

Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican Republic()
por: Steiner, M.J., et al.
Publicado: (2019)

Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem
por: Veisi, Firoozeh, et al.
Publicado: (2013)

Contraception in the Era of COVID-19
por: Nanda, Kavita, et al.
Publicado: (2020)

New approaches for developing biomarkers of hormonal contraceptive use
por: Sachdeva, Rakhee, et al.
Publicado: (2023)

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
por: Karkada, Mohan, et al.
Publicado: (2013)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model
por: Hu, Jiafen, et al.
Publicado: (2022)

Potential biomarkers to predict return to fertility after discontinuation of female contraceptives—looking to the future
por: Cordova-Gomez, Amanda, et al.
Publicado: (2023)

Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature
por: Kahyaoğlu, Serkan, et al.
Publicado: (2017)

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study
por: Thurman, Andrea R., et al.
Publicado: (2022)

Oxidative Stress, Lipid Profile and Liver Functions in Average Egyptian Long Term Depo Medroxy Progesterone Acetate (DMPA) Users
por: Faddah, L. M., et al.
Publicado: (2005)

Structural biology and functional features of phage-derived depolymerase Depo32 on Klebsiella pneumoniae with K2 serotype capsular polysaccharides
por: Cai, Ruopeng, et al.
Publicado: (2023)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Real‑world study of Cerviron(®) vaginal ovules in the treatment of cervical lesions of various etiologies
por: Petre, Izabella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_maqm44rl1ahv901n1laufquqjm